NCT03234361View on ClinicalTrials.gov

Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Hypertension
Interventions
DIETARY_SUPPLEMENT

High Phosphate Phase

2 capsules of sodium phosphate with 500mg/day of phosphate.

DIETARY_SUPPLEMENT

Low Phosphate Phase

2 capsules of sodium chloride.

Trial Locations (2)

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03234361 - Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate | Biotech Hunter | Biotech Hunter